Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HK1 | P19367 | 3/20 | 0.40 |
| ▸ | HK2 | P52789 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.38 |
| ▸ | CD69 | Q07108 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18309824 | 1.00 | MAPK1 (0.49) | MAPK1ALDH1A1THRBLMNAKDM4E | |
| SCHEMBL12023177 | 1.00 | MAPK1 (0.49) | MAPK1ALDH1A1THRBLMNAKDM4E | |
| N-Acetylglucosamine SCHEMBL20621758 | 0.86 | MAPK1 (0.63) | MAPK1ALDH1A1THRBLMNAKDM4E | |
| N-Acetylglucosamine SCHEMBL22748755 | 0.86 | MAPK1 (0.63) | MAPK1ALDH1A1THRBLMNAKDM4E | |
| N-Acetylglucosamine SCHEMBL22264045 | 0.86 | MAPK1 (0.63) | MAPK1ALDH1A1THRBLMNAKDM4E | |
| N-Acetylglucosamine SCHEMBL24978032 | 0.86 | MAPK1 (0.63) | MAPK1ALDH1A1THRBLMNAKDM4E | |
| N-Acetylglucosamine SCHEMBL24105621 | 0.86 | MAPK1 (0.63) | MAPK1ALDH1A1THRBLMNAKDM4E | |
| N-Acetylglucosamine SCHEMBL24276732 | 0.86 | MAPK1 (0.63) | MAPK1ALDH1A1THRBLMNAKDM4E | |
| N-Acetylglucosamine SCHEMBL20798032 | 0.86 | MAPK1 (0.63) | MAPK1ALDH1A1THRBLMNAKDM4E | |
| N-Acetylglucosamine SCHEMBL25229254 | 0.86 | MAPK1 (0.63) | MAPK1ALDH1A1THRBLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170204444-A9 | CHEMOENZYMATIC SYNTHESIS OF HEPARIN AND HEPARAN SULFATE ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170016040-A1 | CHEMOENZYMATIC SYNTHESIS OF HEPARIN AND HEPARAN SULFATE ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-01-19 | — | — | US | disclosed |
| US-9290530-B2 | Chemoenzymatic synthesis of heparin and heparan sulfate analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-03-22 | — | — | US | disclosed |
| US-20140235575-A1 | CHEMOENZYMATIC SYNTHESIS OF HEPARIN AND HEPARAN SULFATE ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235575-A1 | CHEMOENZYMATIC SYNTHESIS OF HEPARIN AND HEPARAN SULFATE ANALOGS | HPSE, ENGASE, GALE | MAPK1 1972/4885ALDH1A1 581/4885THRB 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.